TY - JOUR
T1 - Angiotensin II affects basal, pulsatile, and glucose-stimulated insulin secretion in humans
AU - Fliser, Danilo
AU - Schaefer, Franz
AU - Schmid, Daniela
AU - Veldhuis, Johannes D.
AU - Ritz, Eberhard
PY - 1997/11
Y1 - 1997/11
N2 - Angiotensin II (Ang II) modulates the tissue response to insulin (insulin sensitivity), but the effect of Ang II on the secretion of insulin has nor been investigated thus far. Nineteen healthy volunteers (17 male; mean age, 26 ± 1 years) were studied. In a double-blind, randomized, placebo-controlled study, seven volunteers were allocated on three occasions in random order after an overnight fast to three interventions: (1) solvent (placebo) infusion: (2) infusion of 1.0 ng Ang II · kg-1 · min-1 (subpressor dose); and (3) infusion of 5.0 ng Ang II · kg-1 · min-1 (pressor dose). Frequent blood samples (each minute) were obtained for estimation of plasma insulin concentrations over a period of 120 minutes to assess basal and pulsatile insulin secretion. In an ancillary study, plasma glucose and insulin levels were measured after an oral glucose tolerance test while solvent (placebo) or Aug II was infused in 12 fasting healthy volunteers. Plasma insulin concentrations were measured immunoenzymatically (enzyme-linked immunosorbent assay). Insulin secretion pulses were analyzed with the deconvolution technique, and the regularity of insulin secretion was analyzed with the approximate entropy technique. Plasma insulin half-life was assessed using the hyperinsulinemic euglycemic clamp method. The presser dose of Ang II reduced total, basal, and pulsatile insulin secretion, and this effect was highly significant (P<.01). The subpressor dose tended to suppress insulin secretion. The burst frequency (number of peaks) and the regularity of insulin secretion were not affected by administration of Ang II. After the oral glucose load, the insulinemic response was significantly lower and plasma glucose concentrations were significantly higher with infusion of Ang II compared with placebo. Aug II affects both the basal (nonpulsatile) and the pulsatile component of spontaneous insulin secretion and the glucose- stimulated insulin secretion in humans. This observation is of potential interest with respect to the interaction of Ang II and insulin, eg, in the genesis of hyperinsulinemia and hypertension.
AB - Angiotensin II (Ang II) modulates the tissue response to insulin (insulin sensitivity), but the effect of Ang II on the secretion of insulin has nor been investigated thus far. Nineteen healthy volunteers (17 male; mean age, 26 ± 1 years) were studied. In a double-blind, randomized, placebo-controlled study, seven volunteers were allocated on three occasions in random order after an overnight fast to three interventions: (1) solvent (placebo) infusion: (2) infusion of 1.0 ng Ang II · kg-1 · min-1 (subpressor dose); and (3) infusion of 5.0 ng Ang II · kg-1 · min-1 (pressor dose). Frequent blood samples (each minute) were obtained for estimation of plasma insulin concentrations over a period of 120 minutes to assess basal and pulsatile insulin secretion. In an ancillary study, plasma glucose and insulin levels were measured after an oral glucose tolerance test while solvent (placebo) or Aug II was infused in 12 fasting healthy volunteers. Plasma insulin concentrations were measured immunoenzymatically (enzyme-linked immunosorbent assay). Insulin secretion pulses were analyzed with the deconvolution technique, and the regularity of insulin secretion was analyzed with the approximate entropy technique. Plasma insulin half-life was assessed using the hyperinsulinemic euglycemic clamp method. The presser dose of Ang II reduced total, basal, and pulsatile insulin secretion, and this effect was highly significant (P<.01). The subpressor dose tended to suppress insulin secretion. The burst frequency (number of peaks) and the regularity of insulin secretion were not affected by administration of Ang II. After the oral glucose load, the insulinemic response was significantly lower and plasma glucose concentrations were significantly higher with infusion of Ang II compared with placebo. Aug II affects both the basal (nonpulsatile) and the pulsatile component of spontaneous insulin secretion and the glucose- stimulated insulin secretion in humans. This observation is of potential interest with respect to the interaction of Ang II and insulin, eg, in the genesis of hyperinsulinemia and hypertension.
KW - Angiotensin II
KW - Glucose tolerance
KW - Hyperinsulinemia
KW - Insulin secretion
UR - http://www.scopus.com/inward/record.url?scp=0030667938&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030667938&partnerID=8YFLogxK
U2 - 10.1161/01.HYP.30.5.1156
DO - 10.1161/01.HYP.30.5.1156
M3 - Article
C2 - 9369270
AN - SCOPUS:0030667938
SN - 0194-911X
VL - 30
SP - 1156
EP - 1161
JO - Hypertension
JF - Hypertension
IS - 5
ER -